About our Company
Resource Center

News

FDA Clears Interlace Medical’s MyoSure™ Hysteroscopic Tissue Removal System for The Treatment of Submucosal Fibroids

Framingham, MA, October 28, 2009 (BUSINESS WIRE) - Interlace Medical, Inc., today announced that it has received 510K clearance from the U. S. Food and Drug Administration (FDA) to market the MyoSure Hysteroscopic Tissue Removal System for the removal of submucosal fibroids and polyps.
go Read the Press Release (PDF)

John P. McDonough Joins Interlace Medical’s Board of Directors

Framingham, MA, July 27, 2009 (BUSINESS WIRE) - Interlace Medical is pleased to announce that John P. McDonough has joined the company’s Board of Directors effective July 10th.
go Read the Press Release (PDF)

Interlace Medical Corporation Secures $20.5 Million

Framingham, MA, June 15, 2009 - Baird Venture Partners and HLM Venture Partners-led VC Syndicate Backs Leading Women’s Health Company
go Read the Press Release (PDF)

 

Events

AAGL - 38th Global Congress of Minimally Invasive Gynecology

Come visit us at Booth Number 219.
go Learn more